Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23245098 | 0.98 | NPC1 (0.43) | NPC1KMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL25617606 | 0.95 | NPC1 (0.43) | NPC1KMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL23245021 | 0.94 | NPC1 (0.41) | NPC1KMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL23245075 | 0.88 | ALDH1A1 (0.41) | KMT2AL3MBTL1ALDH1A1HPGDNPSR1 | |
| SCHEMBL23245047 | 0.88 | MAPT (0.48) | KMT2AL3MBTL1ALDH1A1HPGDNPSR1 | |
| SCHEMBL28480547 | 0.88 | KMT2A (0.37) | NPC1KMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL25619323 | 0.87 | NPC1 (0.43) | NPC1KMT2AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL21410471 | 0.86 | L3MBTL1 (0.42) | KMT2AL3MBTL1ALDH1A1HPGDNPSR1 | |
| SCHEMBL28480820 | 0.86 | L3MBTL1 (0.42) | KMT2AL3MBTL1ALDH1A1HPGDNPSR1 | |
| SCHEMBL23245063 | 0.86 | ALDH1A1 (0.50) | KMT2AL3MBTL1ALDH1A1HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774743-B1 | PRODRUG COMPOUNDS ACTIVATED BY AKR1C3 AND THEIR USE FOR TREATING HYPERPROLIFERATIVE DISORDERS | ACHILLES MEDICAL LTD (NZ) | 2023-11-22 | — | — | EP | claimed |
| US-11661404-B2 | Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders | ACHILLES MEDICAL LIMITED (NZ) | 2023-05-30 | — | — | US | claimed |
| US-20210115002-A1 | PRODRUG COMPOUNDS ACTIVATED BY AKR1C3 AND THEIR USE FOR TREATING HYPERPROLIFERATIVE DISORDERS | ACHILLES MEDICAL LIMITED (NZ) | 2021-04-22 | — | — | US | claimed |
| EP-3774743-B1 | PRODRUG COMPOUNDS ACTIVATED BY AKR1C3 AND THEIR USE FOR TREATING HYPERPROLIFERATIVE DISORDERS | ACHILLES MEDICAL LTD (NZ) | 2023-11-22 | — | — | EP | disclosed |
| US-11661404-B2 | Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders | ACHILLES MEDICAL LIMITED (NZ) | 2023-05-30 | — | — | US | disclosed |
| US-20210115002-A1 | PRODRUG COMPOUNDS ACTIVATED BY AKR1C3 AND THEIR USE FOR TREATING HYPERPROLIFERATIVE DISORDERS | ACHILLES MEDICAL LIMITED (NZ) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661404-B2 | Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders | AKR1C2, AKR1C1, AKR1B1 | NPC1 1212/4885KMT2A 2675/4885L3MBTL1 4126/4885 |
| US-20210115002-A1 | PRODRUG COMPOUNDS ACTIVATED BY AKR1C3 AND THEIR USE FOR TREATING HYPERPROLIFERATIVE DISORDERS | AKR1C2, AKR1C1, AKR1B1 | NPC1 1212/4885KMT2A 2675/4885L3MBTL1 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.